Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient
نویسندگان
چکیده
منابع مشابه
Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
IMPORTANCE Immunosuppressed patients with solid organ transplants have an increased risk for nonmelanoma skin cancer. Vismodegib has been reported to be effective for select locally advanced or metastatic basal cell carcinomas. However, there is no data documenting the use and safety of vismodegib in immunosuppressed organ transplant patients. OBSERVATIONS We describe a 78-year-old white man ...
متن کاملU.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
The data and regulatory considerations leading to the U.S. Food and Drug Administration (FDA) January 30, 2012 approval of Erivedge (vismodegib) capsules for the treatment of patients with recurrent, locally advanced, or metastatic basal cell carcinoma (BCC) are described. The FDA's approval decision was based primarily on the results observed in a single-arm, parallel cohort, international tri...
متن کاملConcurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
IMPORTANCE Vismodegib is a targeted agent recently approved for treating patients who develop recurrent or locally advanced basal cell carcinoma (BCC), and will inevitably be integrated into existing therapy for advanced BCC as it becomes increasingly used. Improved understanding of how vismodegib interacts with other treatment modalities, including radiotherapy, would help optimize multidiscip...
متن کاملVismodegib (erivedge) for advanced Basal cell carcinoma.
Vismodegib (Erivedge) for advanced basal cell carcinoma.
متن کاملEpidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
SHORT COMMUNICATION Vismodegib, a Hedgehog (Hh) pathway inhibitor, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of locally advanced (la) and metastatic (m) basal cell carcinoma (BCC). Interim results of the largest clinical study of vismodegib have shown complete (17.5%) or partial (39.8%) response, and stable (39.0%) or progressive (2.8%) disease in 251 c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the European Academy of Dermatology and Venereology
سال: 2017
ISSN: 0926-9959
DOI: 10.1111/jdv.14430